NEWS | alsv

Companies in the News

EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results

Data Presented at Late-Breaking Session at Heart Rhythm Society 2023: Paves Way for Premarket Approval Application for Federal Drug...

Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement

Multi-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways...

Sana Biotechnology Announces Preclinical Data Published in Nature Communications

Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic...

Ring Therapeutics Raises $86.5M in Series C Funding to Create Next Generation Programmable Medicines

Ring raised a total of $86.5 million from new and returning investors, validating its unique approach to creating next-generation...

Aera Therapeutics Launches with $193 M for the Next Generation of Transformative Genetic Medicines

Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range...

Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms

RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human...

eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin

Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated...

DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions

The 1950s are widely recognized as one of the most important decades in biology. This is, in large part, due to the discovery of the...

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of...